Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Business Wire (Thu, 7-May 4:01 PM ET)
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Business Wire (Mon, 27-Apr 4:01 PM ET)
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Business Wire (Thu, 16-Apr 4:01 PM ET)
Business Wire (Wed, 1-Apr 8:01 AM ET)
Market Chameleon (Mon, 26-Jan 4:03 AM ET)
Market Chameleon (Thu, 22-Jan 6:21 AM ET)
Market Chameleon (Thu, 22-Jan 2:35 AM ET)
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics trades on the NASDAQ stock market under the symbol JANX.
As of June 1, 2026, JANX stock price declined to $14.41 with 635,297 million shares trading.
JANX has a beta of 1.33, meaning it tends to be more sensitive to market movements. JANX has a correlation of 0.03 to the broad based SPY ETF.
JANX has a market cap of $878.46 million. This is considered a Small Cap stock.
Last quarter Janux Therapeutics reported $4 million in Revenue and -$.39 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.13.
In the last 3 years, JANX traded as high as $71.71 and as low as $5.65.
The top ETF exchange traded funds that JANX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
JANX has underperformed the market in the last year with a return of -40.1%, while the SPY ETF gained +29.8%. In the last 3 month period, JANX fell short of the market, returning +5.9%, while SPY returned +10.8%. However, in the most recent 2 weeks JANX has outperformed the stock market by returning +3.7%, while SPY returned +2.6%.
JANX support price is $14.23 and resistance is $14.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JANX shares will trade within this expected range on the day.
